This study will use polysomnography, alongside other methodologies such as questionnaires, actigraphic measurements and salivary melatonin samples used in previous studies to investigate sleep quality in patients with i) localized, locally advanced or metastatic hormone sensitive prostate cancer or ii) with full-resected early (stage I-III) epithelial breast cancer. The measurements will be taken before androgen deprivation therapy (ADT - for prostate cancer patients) or endocrine therapy (for breast cancer patients) is initiated, at 6 months and some measures again at 12 months.The groups, defined by cancer type and whether or not treatment includes ADT / endocrine therapy, will be compared to see if there are differences in the prevalence of the lowered sleep quality in the groups.
Written infor med consent according to International Conference on Harmonisation (ICH)/Good Clinical Practice (GCP) regulations before registration and prior to any trial specific procedures
Histologically proven adenocarcinoma of the prostate
Eastern Cooperative Oncology Group performance status 0-2
Adult male patient > 18 years of age, no upper age limit
Histology with predominant small cell prostate cancer
Any previous treatment with ADT or oral AR-targeted agent (exception for short course anti-androgens - disease flare)
Have not received systemic treatment for any other cancer within the last 12 months
Active secondary malignancy that requires systemic therapy